Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年3月10日
	新闻
	China's NMPA Accepts MAA for Foritinib in ALK+ Advanced NSCLC - OncLive OncLive China's NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer. 标记为不相关
	Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC Cancer Network At 9 months, the estimated PFS rates were 56% (95% CI, 47%-64%) and 40% (95% CI, 32%-48%), respectively. Read more. Non-Small Cell Lung Cancer (NSCLC). 标记为不相关
	China's NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC OncLive Lung CancerGlobal Oncology. Advertisement. "We are very pleased that the second indication of…sac-TMT has been approved for marketing, which is ... 标记为不相关
	Pfizer's Talzenna therapy accepted for use within NHS Scotland - PharmaTimes PharmaTimes It is also the second most common cause of death from cancer in Scottish men after lung cancer. Approximately 10%-20% of prostate cancer patients ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈